A survey about the degree of information and awareness of adolescents regarding vaccination in a Province of Central Italy.

Background: Understanding the level of awareness in adolescents on the value of vaccination is kay to developing a proper culture of prevention to counter vaccine hesitancy and the decrease in vaccination coverages. Study design: The aim of the survey was to evaluate awareness, attitudes, opinions, skills and knowledge about vaccines in a group of Italian adolescents through a paper-and-pencil questionnaire. Methods: The questionnaire was administered to adolescents who had appointments in two vaccination centers of the Public Health Authority of Latina (Latium, Italy), between August 2018 and January 2019. Results: In total, 391 forms were completed by teenagers (median age 16 years, 52% females), Results showed that 53% of participants were not aware of their vaccination status. Knowledge, assessed through questions about vaccines and preventable diseases, was generally poor. However, 89% of adolescents had a positive opinion about vaccinations. Spontaneous searches for vaccine information was low (28.7% had looked for information), despite the medium to high interest expressed. The participants usually sought information on vaccines on generic websites (52.8%) compared to getting information from paediatricians (20.4%) or other physicians (3.7%). However, participants recognized paediatricians/GPs (47%) and schools (46.2%) as the most reliable sources of information. Conclusions: Findings are in agreement with previous published data and can be useful to school and health educators in order to teach adolescents about the value of prevention, providing them with the support necessary to improve their abilities and knowledge.

Validation of an Italian tool to assess vaccine literacy in adulthood vaccination: a pilot study.

Vaccine Literacy (VL) is based on the same idea of Health Literacy (HL): it involves people's knowledge, motivation and competence to find, understand and use information to take decisions about children's and adults' vaccination. Using general measures, the association between HL and Vaccine Hesitancy has been shown to be inconsistent. HLVa-IT is a new tool, specific for the self-assessment of three VL scales, functional, interactive and critical about adults' immunization. Following a face validation process, HLVa-IT has been used to assess VL levels in a population of 50-75 years of age at the Public Health Unit of Latina (Latium, Italy). In order to validate its theoretical construct, it was administered at the same time with a Vaccine Quiz (VQ), assuming that subjects showing good knowledge about vaccination should have adequate VL. The consistent positive correlation for all three VL scales with the VQ score (Spearman's r=0.320, P=0.0004; r=0.389. P=0.0001 and r=0.306, P=0.0022, respectively), as well as with the educational degree, confirm the valid construct of HLVa-IT. A criterion validity of this tool has also been sought verifying its relation with acceptance of vaccines (VA) recommended in the adult/senior age. A positive association with VA observed only on the functional scale in the population ≥ 65 years, does not permit to accept a predictive validity, confirming that direct effect of Health Literacy is more clearly verifiable on knowledge than behavior outcomes. Nevertheless, HLVa-IT has shown suitable psychometric characteristics for the subjective measure of VL in individuals and in population studies. It is desirable that more specific tools are validated and extensively used, with the aim of assessing peoples' VL skills and defining interventions aimed at their improvement.

An Italian validation of "meter", an easy-to-use Health Literacy (hl) screener.

Health Literacy (HL) is the degree to which individuals have the capability to obtain, understand and process basic health information needed to make appropriate health decisions. It affects persons' ability to access and use health care, to interact with providers, and to care for themselves. Established literacy screeners have practical limitations (such as practictioner's attendance, time to complete, etc.): to address these, a short, self-administered measure of HL, the Medical Term Recognition Test (METER) was introduced in USA. In this study an Italian version (IMETER) of this measure has been validated administering it to undergraduate students, attending Medicine, Arts and Engineering faculties. The results of this study show a high degree of reliability and validity of the test when comparing the skills of students educated in medical matters and those of non-biological faculties, indicating the potential capability of the tool to screen low HL levels in larger population. Despite the limits of this pilot study, IMETER's quick and easy administration method seems useful not only in clinical settings, but also to ease the implementation of future larger studies.

Universal varicella vaccination in the Sicilian paediatric population: rapid uptake of the vaccination programme and morbidity trends over five years.

Following the licensure of the Oka/Merck varicella vaccine in Italy in January 2003, the Sicilian health authorities launched a universal vaccination programme in all nine Local Health Units. A two-cohort vaccination strategy was adopted to minimise the shift of the mean age of varicella occurrence to older age groups, with the goal of vaccinating with one dose at least 80% of children in their second year of life and 50% of susceptible adolescents in their 12th year of life. Two studies were implemented in parallel to closely monitor vaccination coverage as well as varicella incidence.

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

A randomised, open study was carried out among an elderly population in order to compare the reactogenicity and immunogenicity of an inactivated, split virion influenza vaccine (Vaxigrip, Aventis Pasteur MSD, Lyon, France) with that of an MF59-adjuvanted, subunit vaccine (Fluad, Chiron Vaccines, Siena, Italy). Both vaccines contained the three strains: A/Sydney/5/97 (H3N2), A/Beijing/262/95 (H1N1) and B/Beijing/184/93, recommended by the WHO for the 1998-1999 influenza season. A total of 2150 subjects were vaccinated and included in the reactogenicity analysis. A total of 1076 subjects received Vaxigrip (age 73.3 +/- 5.9 years, 49.6% men) and 1074 subjects received Fluad (age 73.4 +/- 5.9 years, 52.3% men). All subjects were kept under medical observation for 30 min after vaccination, in order to check any immediate local and/or systemic reaction. A self monitoring diary card was given to all subjects to collect any local and/or systemic reaction occurring during the 3 days following the vaccination, any adverse event occurring between vaccination day and 21st day post-vaccination and any medication taken during the study period. A total of 1186 subjects were included in the immunogenicity analysis. A total of 591 subjects received Vaxigrip (age 73.4 +/- 5.6 years, 52.3% men) and 595 subjects received Fluad (age 73.8 +/- 5.9 years, 55.8% men). Blood samples were collected pre- and 21 days post-vaccination and were analysed by the haemagglutination inhibition assay. In terms of reactogenicity both vaccines were generally well tolerated. The frequency of local reactions was lower in the group that received Vaxigrip. Pain at the injection site occurring from 30 min to 3 days after vaccination was also significantly less frequent (P = 0.005) in the Vaxigrip group. Fever > or =37.5 degrees C was reported in less than 1% of all vaccinated subjects. No serious adverse event was related to vaccine administration. In terms of immunogenicity both vaccines induced an effective immune response (anti-HI titre > or =40) against A/Sydney/5/97 (H3N2) and A/Beijing/262/95 (H1N1) strains in the entire population. Vaxigrip and Fluad induced similar seroprotection and seroconversion rates against the A/Sydney/5/97 (H3N2) strain. For both vaccines a lower percentage of subjects achieved a seroprotective titre > or =40 against the B/Beijing/184/93. A lower antibody response against the influenza B strain was also observed in other studies conducted during the same season. In subjects 75 years of age or older, Fluad was more immunogenic than Vaxigrip for all three virus strains.

Safety and immunogenicity of a conjugate vaccine against Haemophilus influenzae type b in splenectomized and nonsplenectomized patients with Cooley anemia.

Patients with thalassemia are at increased risk for infections, especially after undergoing splenectomy. Vaccinations and antimicrobial prophylaxis are recommended in these patients, but the optimal immunization schedule for Haemophilus influenzae type b (Hib) vaccine is unknown. The immunogenicity of a conjugate Hib vaccine was investigated in 57 patients with thalassemia, 32 of whom had undergone splenectomy. Anti-capsular antibodies to Hib (anti-polyribosylribitol phosphate) were measured before vaccination and 2, 6, 12, 24, and 36 months after vaccination. Immunization was well tolerated. All patients achieved protective (>1 microg/mL) antibody levels. Antibody titers declined after the initial postvaccination increase, becoming undetectable in 4 patients and decreasing to concentrations of 0.15-1 microg/mL in another 2 patients when tested 2-3 years after vaccination. Hib conjugate vaccine is safe and immunogenic in patients with thalassemia major; however, additional studies are needed to assess the need and timing of booster vaccination to maintain long-term immunity.

Simultaneous influenza and pneumococcal vaccination in elderly individuals.

The study was performed to evaluate the effects of influenza and pneumococcal vaccines administered alone or in combination. 124 elderly subjects living in community were vaccinated either with influenza split vaccine or with pneumococcal 23-valent or with both vaccines at the same time in different sites. Sera were tested for hemoagglutination inhibiting antibodies for influenza and for antibodies against 23-valent vaccine for streptococcus pneumoniae. No side effects were observed in the vaccinated population. Serological results indicated that influenza vaccine increased significantly antibody levels. No difference was observed between the group which received influenza vaccine alone and that which received influenza and pneumococcal vaccines associated, considering either G.M.T or the percentages of protected individuals or the percentages of subjects who seroconverted. When pneumococcal vaccine was administered at the same time with influenza vaccine, there was a not statistically significant reduction in both mean antibody concentration and mean fold increase. It is concluded that the simultaneous administration of influenza and pneumococcal vaccines to elderly individuals, including subjects at risk, is safe, effective and economically advantageous.

Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users.

The humoral response (haemagglutination inhibiting antibodies) to trivalent split influenza vaccine for the 1993-94 winter season (A/Beijing/32/92 (H3N2), A/Singapore/6/86 (H1N1) and B/Panama/45/90) was evaluated in a group of young HIV-seropositive ex-intravenous heroin users and compared with responses measured in HIV-seronegative individuals with a similar history. HIV-negative volunteers showed an overall positive response suggesting that previous heroin use did not influence their humoral response to influenza vaccine. Comparable results were obtained in HIV-positive subjects with CD4+ lymphocyte counts > 500 microliters-1, whereas impaired reactivity was found in HIV-positive volunteers with CD4+ counts < 500 microliters-1. Booster vaccination did not increase antibody levels in any of the groups studied, although the data did not exclude a positive influence of a second vaccine dose on persistence of antibody at 120 days after the first dose. No significant changes were observed in p24 antigenemia levels in HIV-positive individuals after vaccination.

Immune response to a booster dose of enhanced potency inactivated polio vaccine administered in association with HBV vaccine in adolescents.

The immunogenicity and reactogenicity of a booster dose of enhanced potency inactivated polio vaccine (EIPV) were evaluated in 492 healthy 12 year old adolescents. The booster was administered at the same time as the HBV vaccine compulsory in Italy at this age. Blood samples and questionnaires on reactogenicity were collected over 9 months. Analysis of pre-vaccination immunity showed that 97.4% of the subjects were protected against all polio types, 1.9% were negative for two polio types and 0.6% for one. After vaccination 98.4% of the vaccinees showed a significant increase ( > or = 4 times) of antibody titre; the geometric mean titres (GMT) were markedly higher than before vaccination, particularly for poliovirus type 3. The polio booster dose did not affect HBV vaccination. An anti-HBs response > 10 mIU ml-1. (GMT = 2951 mIU ml-1) was observed in 781 (98.6%) of 792 vaccinees (492 given EIPV+HBV and 300 given only HBV) 9 months later. Only mild local and rare general reactions were noted for both the vaccines studied. These data confirm the suitability and efficacy of an EIPV booster dose and HBV vaccination in adolescents.

[Incidence of Haemophilus influenzae type b meningitis in Italy. Preliminary results]. / Incidenza delle meningiti da Haemophilus influenzae tipo b in Italia. Risultati preliminari.

The Authors describe the survey's results aimed at quantifying the Haemophilus influenzae type b meningitis incidence rate in Italy. The survey collected all the cases of 1994 notified per region to the Ministry of Health; furthermore, regional incidence rates are compared and integrated with other data obteined from local ad hoc studies. The results obtained show a high incidence in the age group 0-2 years and a large discrepancy in the incidence rate between regions (from 0.0 to 16.8 cases per 100,000); furthermore, in the same age group, for a large amount of meningitis cases (18% of the total) the aetiological diagnosis was not successful; this phaenomenon is certainly one of the causes for the underestimation of the disease. The integration with data collected in longitudinal studies, increases largely the regional incidence rate, showing the highest rate in the Lazio Region (18.5 cases per 100,000). The Authors conclude by stressing the need to increase the cooperation between the Regional Health Authorities and the Ministry of Health, in order to obtain more reliable figures of the national incidence rates.

Attitudes and behavior of health care personnel regarding influenza vaccination.

This paper reports the results of a study conducted by the Italian Association for Immune-Prophylaxis Promotion (AIP.I) with the aim of surveying the attitudes and perceptions of Italian health care workers regarding the use and efficacy of influenza vaccine. The results clearly show that a high proportion of the questioned health care workers showed a general lack of concern about the severity of the disease. Doubts about vaccine efficacy and fear of post-vaccination side effects were also observed to have an important influence on the vaccination acceptance rates. These data underline the need for a systematic education program to provide influenza vaccination within the public and private health-care sectors in Italy.